Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of deuterium depleted water for the treatment of insulin resistance

A technology of insulin resistance and deuterium-depleted water, which is applied in the fields of carbohydrate active ingredients, medical preparations containing active ingredients, food science, etc., can solve problems such as DDW treatment of insulin resistance, etc.

Inactive Publication Date: 2013-04-24
HYD癌症研究和药物开发有限公司
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the patent's description makes no mention that DDW is suitable for treating insulin resistance, nor that water with a D-level of 105-125 ppm is optimal for this effect (see below)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of deuterium depleted water for the treatment of insulin resistance

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0040] The preparation of pharmaceutical products is carried out by methods standard in the art by mixing the active agent with an inert, inorganic or organic carrier and then preparing a galenical form from this mixture. A practical carrier is water.

[0041] The drug product may also contain other auxiliary components commonly used in the pharmaceutical industry (such as wetting agents, sweetening or flavoring agents, buffer solutions).

[0042] The daily dosage of the medicine according to the present invention can be varied and depends on various factors, such as the D concentration of the water, the age and weight of the patient, the type and severity of diabetes, and the like. For a 70 kg patient, the daily oral dose may be 0.01-2L DDW with a D concentration of 0.01-135 ppm. To enhance organoleptic properties and biological effects, the water may contain eg 20-30 g / L low D carbohydrates, certain low D amino acids or other flavors and fragrances.

[0043] The advantages...

Embodiment

[0051] Below illustrate the present invention with more detailed content, rather than limit protection scope:

[0052] A) Pharmacological Examples

[0053] In a rat model system, streptozotocin (STZ)-pretreated animals were treated with water with different deuterium concentrations for 4 weeks in several independent experiments. Rats received insulin treatment of 1 IU twice a day, the control group consumed normal water (150 ppm), while the treated groups consumed DDW at 25, 70, 105, 125, 130, 135, 140 and 145 ppm D levels. To find out what mechanism is responsible for the lower blood glucose levels in rats drinking DDW, the amount of GLUT4 protein in rat muscle cell membranes was determined. figure 1 The two rightmost blank bars in , show that in rats not pretreated with STZ, the amount of GLUT4 was not affected by the D concentration (25-150 ppm) of the water they consumed. The five dark bars on the left side of the figure show that in STZ-pretreated rats, the lowest GLUT4...

Embodiment 1

[0055] Formulation Example 1: Preparation of Drinking Water with Beneficial Mineral Composition

[0056] Mix low D water with mineral water of known composition (such as "Csillaghegyi" or "Balfi") in the following proportions:

[0057] a / 0.25 parts 90ppm DDW + 0.75 parts mineral water by volume (final D concentration: 135ppm);

[0058] b / 0.5 parts 90ppm DDW + 0.5 parts mineral water by volume (final D concentration: 120ppm);

[0059] c / 0.75 parts 90ppm DDW + 0.25 parts mineral water by volume (final D concentration: 105ppm);

[0060] d / 0.25 parts by volume 60ppm DDW + 0.75 parts mineral water (final D concentration: 127.5ppm);

[0061] e / 0.5 parts by volume 60ppm DDW + 0.5 parts mineral water (final D concentration: 105ppm);

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates deuterium depleted water containing 0.01 to 135 ppm deuterium, preferably 105 to 125 ppm deuterium, for use in the treatment of insulin resistance. Further object of the invention is deuterium depleted food product containing 0.01 to 135 ppm deuterium, preferably 105 to 125 ppm deuterium, for use in the treatment of insulin resistance.

Description

[0001] The present invention relates to medicine and food containing deuterium depleted water suitable for treating insulin resistance. technical background [0002] Diabetes mellitus (DM) is a chronic disease of human metabolism. The disease is caused by a lack of insulin (a hormone produced by the pancreas) or an insensitivity to insulin in the body (insulin resistance, a relative lack of insulin), or both. Cells are unable to use glucose due to an absolute or relative lack of insulin, which is why elevated blood sugar levels (hyperglycemia) cause the symptoms of the disease. In this case, the patient's blood glucose level is above the normal range of 3.5-6.5 mmol / L. The following is common to people in this disease group: despite differing pathogenesis, they all fail to secrete the amount of insulin required for their metabolic processes, or insulin does not work despite its presence. [0003] Diabetes mellitus (DM) has three subgroups in terms of diagnosis: [0004] 1. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P3/10A23L33/00
CPCA61K33/00A61P3/08A61P3/10A61K31/70A61K38/00
Inventor 佳伯·索姆利艾
Owner HYD癌症研究和药物开发有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com